Generation Bio Co. (NASDAQ:GBIO) Short Interest Update

Generation Bio Co. (NASDAQ:GBIO) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 1,910,000 shares, an increase of 13.7% from the June 30th total of 1,680,000 shares. Based on an average daily trading volume, of 159,100 shares, the days-to-cover ratio is currently 12.0 days. Currently, 3.9% of the shares of the company are short sold.

Analyst Ratings Changes

Several research analysts have issued reports on GBIO shares. Wedbush reissued an “outperform” rating and set a $5.00 price objective on shares of Generation Bio in a research report on Tuesday, May 14th. Needham & Company LLC reissued a “buy” rating and set a $10.00 price target on shares of Generation Bio in a report on Tuesday, May 14th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.00.

Generation Bio Stock Performance

GBIO traded down $0.40 during trading on Monday, hitting $3.11. The stock had a trading volume of 75,934 shares, compared to its average volume of 218,021. Generation Bio has a twelve month low of $0.86 and a twelve month high of $5.50. The company’s 50-day moving average price is $2.94 and its 200 day moving average price is $2.85.

Generation Bio (NASDAQ:GBIO) last posted its quarterly earnings results on Monday, May 13th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.76). Generation Bio had a negative return on equity of 82.33% and a negative net margin of 1,696.87%. The firm had revenue of $4.06 million for the quarter, compared to analysts’ expectations of $3.02 million. On average, sell-side analysts predict that Generation Bio will post -1.68 earnings per share for the current year.

Institutional Trading of Generation Bio

A number of institutional investors have recently modified their holdings of GBIO. Price T Rowe Associates Inc. MD raised its position in Generation Bio by 28.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,878,361 shares of the company’s stock worth $36,136,000 after acquiring an additional 1,952,187 shares in the last quarter. Baker BROS. Advisors LP purchased a new position in shares of Generation Bio in the 1st quarter valued at about $1,511,000. Acadian Asset Management LLC lifted its stake in shares of Generation Bio by 113.9% in the first quarter. Acadian Asset Management LLC now owns 479,835 shares of the company’s stock valued at $1,952,000 after purchasing an additional 255,468 shares during the period. Bellevue Group AG boosted its holdings in Generation Bio by 6.8% during the first quarter. Bellevue Group AG now owns 3,861,575 shares of the company’s stock worth $15,717,000 after buying an additional 244,495 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in Generation Bio by 315.6% during the fourth quarter. Los Angeles Capital Management LLC now owns 275,834 shares of the company’s stock worth $455,000 after buying an additional 209,462 shares during the period. 95.22% of the stock is currently owned by hedge funds and other institutional investors.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.